Orforglipron: The GLP-1 Pill That Skips the Needle

Key Takeaway

In a 72-week phase 3 trial of 238 Japanese adults with obesity-related disease, a once-daily oral pill called orforglipron reduced body weight by up to 8.7%, compared with 0.6% on placebo. Side effects were mostly mild-to-moderate stomach upset, the same pattern seen with today’s injectable GLP-1 drugs. Because orforglipron is a small molecule rather than a protein, it could eventually be cheaper and easier to produce at global scale.

The Patient Who Would Not Pick Up the Pen

I once cared for a retired schoolteacher, 58 years old, with high blood pressure and creeping cholesterol. She had tried 3 diets and been told twice that a weekly injection could change everything. Each time she nodded, took the prescription and never filled it. “I faint at needles,” she finally admitted. “I’d rather keep the weight.”

Her story is not rare. The injectable GLP-1 drugs, semaglutide and tirzepatide, have transformed obesity care, with weight losses that once seemed reachable only through surgery^[2]. But they are protein-based drugs that must be injected, and they are complex to manufacture. Supply shortages and needle aversion still keep millions of people away. A pill that does the same job,…